Analyst Emmanuel Papadakis works at DEUTSCHE BANK and is focused on the Healthcare sector with 13 price targets and ratings documented since 2017 spanning on 11 stocks. Analyst's average stock valuation to be materialised ratio is 100% with an average time for price targets to be met of 870 days.
Most recent stock forecast was given on MRNA, Moderna, Inc at 08-Sep-2022.
Emmanuel Papadakis best performing recommendations are on MRNA (MODERNA, INC).
The best stock recommendation documented was for MRNA (MODERNA, INC) at 3/7/2022. The price target of $155 was fulfilled within 9 days with a profit of $28.54 (22.57%) receiving and performance score of 25.08.
Average potential price target upside